HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

  • End date
    Apr 29, 2024
  • participants needed
  • sponsor
    Abramson Cancer Center of the University of Pennsylvania
Updated on 4 October 2022


The main purpose of this research study is to learn whether the investigational combination of olaparib, palbociclib, and fulvestrant is safe in patients with estrogen receptor-positive breast cancer and BRCA1 or BRCA2 mutations.

Condition Metastatic Breast Cancer, Locally Advanced Breast Cancer, BRCA2 Mutation, BRCA1 Mutation, Stage IV Breast Cancer, Advanced Breast Cancer
Treatment olaparib, fulvestrant, Palbociclib
Clinical Study IdentifierNCT03685331
SponsorAbramson Cancer Center of the University of Pennsylvania
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

Females/males age 18
Germline or somatic deleterious or suspected deleterious mutation in BRCA1 or BRCA2
Metastatic or locally advanced unresectable breast cancer that is ER and/or PR positive (>1%) and HER2 nonamplified
Prior treatment with 0-2 prior lines of chemotherapy for metastatic breast cancer
Regarding prior platinum-based chemotherapy
Patients who received prior platinum-based chemotherapy in the adjuvant or neoadjuvant setting for breast cancer are eligible if treatment was completed at least 12 months prior to diagnosis of metastatic disease
Patients who received platinum for advanced breast cancer are eligible to enter the study provided there was no evidence of disease progression during the platinum chemotherapy
Patients who received prior platinum-based as a potentially curative treatment for a prior non-breast cancer (e.g., ovarian cancer) with no evidence of disease for 5 years or greater prior to study entry are permitted
Deemed a candidate for endocrine therapy (any prior endocrine therapy is permitted; no prior endocrine therapy is also permitted)
Adequate organ and bone marrow function
ECOG performance status 0-1
Life expectancy 16 weeks
At least one measurable disease or disease that can be assessed by CT or MRI
Postmenopausal as defined below. Women who are on pharmacologic ovarian suppression must have two negative urine or serum pregnancy tests: one during screening (within 28 days prior to study treatment) and one within 7 days prior to commencing treatment
Willing to comply with study requirements and procedures including use of appropriate contraception, willingness to discontinue herbal preparations / medications, and study biopsy if archival tissue is not available
Postmenopausal is defined as one of the below
Amenorrheic for 1 year or more following cessation of exogenous hormonal treatments
Follicle stimulating hormone (FSH) levels in the post-menopausal range for women under 50
radiation-induced oophorectomy with last menses >1 year ago
chemotherapy-induced menopause with >1 year interval since last menses
bilateral oophorectomy or hysterectomy
on luteinizing hormone-releasing hormone (LHRH) agonists according to current clinical practice standards as pharmacologic ovarian suppression
Female patients of childbearing potential (not post-menopausal as defined above) must agree to the use of two highly effective forms of contraception in combination throughout the period of taking study treatment and for 1 month after last dose of study drug(s) to prevent pregnancy
Male patients and their sexual partners of childbearing potential must agree to the use of two highly effective forms of contraception in combination throughout the period of taking study treatment and for 3 months after last dose of study drug(s) to prevent pregnancy in a partner

Exclusion Criteria

Involvement in study planning or conduct
Participation in another clinical study with an investigational product during the last 3 weeks
Other malignancy within the last 5 years with exceptions listed in the protocol
Concomitant strong or moderate CYP3A inhibitors/ inducers
Persistent toxicity of prior cancer therapy that is grade 2 except for alopecia or neuropathy
MDS or features suggestive of MDS/AML
Symptomatic uncontrolled brain metastases
Regarding prior olaparib or palbociclib
Patients considered to be at poor medical risk
Phase II: Patients who previously progressed on olaparib or palbociclib for metastatic breast cancer treatment are excluded
QTc >470 msec on 2 or more time points or a family history of long QT syndrome
Unable to swallow or absorb oral medication
Systemic chemotherapy or radiotherapy (except palliative) within 3 weeks of start of study treatment
Immunocompromised patients
Pregnant or breast-feeding
Major surgery within 2 weeks of start of study treatment
Hypersensitivity to olaparib, palbociclib, fulvestrant, or any excipients of these products
Prior bone marrow transplant
Whole blood transfusions 120 days prior to signing consent
Known active hepatitis
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note